Full Press Release Details
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Proof-of-Mechanism of MZE782, a Specific Inhibitor of SLC6A19 for the Treatment of CKD: Phase 1 Study in Healthy Adults
MAZE Positive Sentiment
NOVEMBER 2025 I MAZE THERAPEUTICS
Key Takeaway: The article discusses the Phase 1 study of MZE782, a specific inhibitor of SLC6A19, aimed at treating chronic kidney disease (CKD). The study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamic proof-of-mechanism in healthy adults. The findings suggest a positive outlook for MZE782 as a potential therapeutic option for CKD.
Price reaction · baseline $28.6 (2025-11-07 close) · clean, no other MAZE news in the window
day 0 close
+6.6%
day 1 · peak
+12.8%
day 3
+11.3%
Market Sentiment Analysis
POSITIVE FACTORS
- MZE782 shows promise as a specific inhibitor for SLC6A19.
- The Phase 1 study indicates a focus on safety and tolerability.
- Potential treatment for chronic kidney disease (CKD) is highlighted.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease
Frequently Asked Questions
What is MZE782?
MZE782 is a specific inhibitor of SLC6A19 designed for treating chronic kidney disease.
What does the Phase 1 study evaluate?
The Phase 1 study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of MZE782.
Who participated in the Phase 1 study?
The Phase 1 study involved healthy adults as participants.
What condition is MZE782 targeting?
MZE782 is targeting chronic kidney disease (CKD) for treatment.